The hypogammaglobulinemia of at least 2 immunoglobulin isotypes characterizes the heterogeneous group of the primary immunodeficiency disorder known as common variable immunodeficiency (CVID; OMIM #240500). [1] [2] [3] [4] [5] These patients are particularly susceptible to recurrent infections of the respiratory tract, as well as the gastrointestinal system, and manifest noninfectious complications, such as autoimmunity, gastrointestinal disorders, and lymphoproliferation. 1, 5 Despite the rarity of this condition, CVID is the most common immunodeficiency of clinical significance whose main immunologic defect, the failure of immunoglobulin production, is usually associated with a normal peripheral B-cell counts. 1, 5 Genetic defects associated with survival, differentiation, and/or immune interactions of B cells have been proposed to be responsible for the pathophysiology of the disease. Several attempts aiming to classify patients with CVID have mainly focused on T-or B-cell phenotypes and their ability to produce protective antibodies, 2, 6, 7 but it is still a major challenge to find a suitable classification that includes the clinical and immunologic heterogeneity of these patients and their variable response to treatment. The plasma IgG level has poor predictive value in patients with CVID because patients with slightly decreased IgG levels can be highly susceptible to infections and benefit from replacement with intravenous gammaglobulin therapy. 8 Nevertheless, the molecular mechanisms underlying the maturation of the antibody response triggered by natural infections and vaccines have been poorly investigated in these patients.
During somatic hypermutation (SHM), point mutations are introduced into the V region of immunoglobulin genes (both IgH as IgL), increasing antibody affinity for the antigen, and this process is essential for the generation of long-lived plasma and memory B cells. [9] [10] [11] Failure in the affinity maturation process of all isotypes of antibodies could underlie a qualitative humoral immunodeficiency. In previous reports impaired SHM was associated with a high frequency of severe respiratory tract infections in a cohort of mainly adult patients with CVID. 12 In addition, antibody response maturation also requires the class-switch recombination (CSR) process, in which the Cm region is replaced by a downstream immunoglobulin CH gene, resulting in a change from IgM to IgG, IgA, or IgE, a mechanism involving S regions located upstream of each CH except Cd. 13 Both SHM and CSR are dependent on activation-induced cytidine deaminase (AICDA) function, an enzyme expressed in antigen-activated B cells that generates high-affinity antibodies and antibody CSR, respectively.
14 To achieve CSR, AICDA generates double-strand breaks (DSBs) mainly repaired through a nonhomologous end-joining (NHEJ) mechanism 15 by using little or no sequence homology. The NHEJ machinery requires a large number of factors (eg, Ku70/Ku80, DNA-PKcs, DNA ligase IV, Artemis and Cernunnos), [16] [17] [18] [19] [20] and defects in this mechanism lead to alternative pathways (eg, use of microhomology) in an attempt to repair DSBs at the S junctions, as shown in patients with primary immunodeficiencies involving defects in NHEJ genes. 21, 22 In this study we evaluated the capacity to perform SHM and CSR ex vivo and in vitro in a population of patients with pediatric-onset CVID whose immunologic and clinical data were previously reported, 23 allowing us to propose 3 different subsets of patients with CVID.
METHODS

Patients and control subjects
This study included 25 unrelated patients with CVID (12 male patients) with a mean age of onset of symptoms of 5.6 years (range, 1-14 years) and a mean age of diagnosis of 11.3 years (range, 4-16.1 years). Mutations in the CD40L, CD40, AICDA, UNG, PMS2, DCLRE1C (ARTEMIS), and DNA LIG4 genes were excluded in patients presenting with normal or with increased IgM levels. Patients with decreased peripheral B-cell counts were also excluded from the study. We considered patients as belonging to the smB 1 (switched memory B cells >2%) or smB2 (switched memory B cells <2%) subgroups, depending on their B-cell immunophenotype, according to the EUROclass CVID classification. 6 These patients were previously reported (Patients Part B), 23 and the main clinical and immunologic data were summarized in Tables I and  II . Informed written consent was obtained from the patient or parental guardian before participation in accordance with the Declaration of Helsinki. Twenty-two healthy donors matched for age, sex (11 male donors), and ethnic background were included in the study and provided written consent under a separate ethics protocol for healthy donors. Five cord blood samples were included as negative controls in the restriction enzyme hotspot mutation assay (IgkREHMA) and were donated after informed consent was obtained from the delivering women. The research protocol was approved by the internal ethics review board of the Hospital Garrahan.
Total RNA preparation and cDNA synthesis Total RNA was extracted from PBMCs by using TRIzol reagent (Invitrogen, Carlsbad, Calif), and cDNA was prepared with a first-strand cDNA synthesis kit (Amersham Biosciences, Little Chalfont, United Kingdom), according to the manufacturer's instructions.
RNA from memory and naive B-cell subsets was obtained by using the RNeasy Micro Kit (Qiagen, Hilden, Germany), whereas cDNA was prepared with SuperScript III (Invitrogen), according to the manufacturer's instructions.
Human cell isolation
PBMCs were isolated by means of density centrifugation over a Ficoll-Hypaque Plus (Amersham) gradient. B cells from 7 patients and 4 healthy donors were purified from PBMCs by means of negative selection with the MACS B Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Memory and naive B-cell subsets were purified from total B cells obtained by using the FACSAria Cell Sorter (BD Biosciences, San Jose, Calif) with CD27-fluorescein isothiocyanate, IgD-phycoerythrin, and CD19-phycoerythrin-Cy7 (all from eBioscience, San Diego, Calif). All fractions were obtained with a purity of greater than 95%.
Cell cultures and reagents
Culture of PBMCs or naive B cells from patients with CVID or healthy donors was performed in complete RPMI medium supplemented with 10% (vol/vol) FBS (Gibco, Grand Island, NY). In the T-dependent (TD) stimulation cells were incubated with 500 ng/mL CD40 ligand (CD40L; PeproTech, Rocky Hills, NJ) and 200 U/mL IL-4 (Schering-Plough, Kenilworth, NJ). CD40 was cross-linked with 1 mg/mL mouse 89 mAb (Schering-Plough). Mouse IgG 1 mAb with irrelevant binding activity (Santa Cruz Biotechnology, Dallas, Tex) was used as a control. In the T-independent (TI) stimulation cells were incubated with 5 mg/mL phosphorothioatemodified 59-tcgtcgttttgtcgttttgtcgtt-39 oligodeoxynucleotide-2006 (Operon Technologies, Olive Branch, Miss) and 50 ng/mL IL-10 (PeproTech).
RT-PCR and quantitative RT-PCR
Quantification of human Ig1-Cg1 or Ia-Ca germline transcripts (GLT), switched Ig1-Ig2-Cm or Ia-Cm circle transcripts (CTs), AICDA transcript, and glyceraldehyde-3-phosphate dehydrogenase was performed from total RNA extraction in 2-or 4-day cultures with TRIzol (Invitrogen). cDNA was generated by mean of reverse transcription with Superscript II RT (Invitrogen). PCR primers and conditions used for standard or quantitative RT-PCR analysis were performed, as previously reported. [24] [25] [26] Results of qRT-PCR were normalized to ACTB mRNA and presented as relative expression compared with that of B cells incubated with control antibody.
Characterization of SHM
The IgkREHMA was performed, as previously described. 12 
Characterization of switch recombination junctions
Genomic DNA was purified from peripheral blood cells from patients and healthy donors by using standard methods. Amplification of Sm-Sa from in vivo switched cells was performed by using a previously described nested PCR assay. 21 The PCR-amplified switch fragments were gel purified (GE Healthcare, Fairfield, Conn) and cloned into pGEM-T vector (Invitrogen), and sequence analysis was performed with DNA Sequencing Analysis software (PE Applied Biosystems, Foster City, Calif) on an ABI 3130 (Applied Biosystems). CSR junctions were determined by aligning the switched fragment sequences with Sm (X54713) and Sa1 (L191219) or Sa2 (AF030305). Analysis of microhomology use and mutation patterns at CSR junctions was performed, as described previously. 21, 27 Statistical analysis Statistical analysis of results was performed with Student 2-tailed t tests by using Prism software (GraphPad Sotware, La Jolla, Calif), Spearman 2-tailed tests, or 1-way ANOVA followed by the Dunnett multiple comparison posttest. Frequencies of noninfectious complications among the groups were compared by using the x 2 test. Other statistical analyses were performed with x 2 tests with SPSS 15.0 software for Windows (IBM, Armonk, NY).
RESULTS
B cells of patients with CVID carry significantly diminished SHM
To evaluate the SHM levels in peripheral cells from our patients, we performed an assay developed by Andersen et al. 12 This assay is based on cleavage by using a restriction enzyme of a hotspot in the rearranged VkA27 transcripts (IgkREHMA).
Briefly, somatic mutations in the restriction sites of the most commonly used light chain gene (kA27) abrogate cutting with a specific enzyme. The variability observed in our healthy control group remained within the levels previously reported (Fig 1, A  and B) , 12 which did not seem to be modified by donor age greater than 2 years.
The comparison of our CVID patient group with the healthy donor group revealed a significant difference in mutations of the VkA27 gene (P <.0001, Student 2-tailed t test; Fig 1, A and B) . At the same time, a heterogeneous behavior in undergoing SHM could be observed in the pediatric population with CVID (Fig 1, A and Almost all of the patients (24/25) had decreased SHM values (Table I) . Based on these results, a relevant cutoff could optimize the distinction of patients with clinical complications, reduced switched memory B-cell counts, or both. Thus we established 2 subgroups of patients with altered SHM: group A with less than 23 SDs with respect to the healthy control group (<18% of the mutated fraction of VkA27) and group B with values ranging between 22 and 23 SDs compared with the healthy control group (> _18% and <28% of the mutated fraction, Table I ). Only 1 patient (P25) had values greater than the reference interval of our healthy control group.
We can see that 88% (14/16) of the patients in group A had a low number of switched memory B cells (<2%) belonging to the so-called smB2 group of EUROclass (see the Methods section), who also showed clinical complications or more severe presentation of the disease (ie, 6/9 patients with autoimmunity, splenomegaly, or granulomas fell into this group; Table I ). On the other hand, 7 of the 8 patients in group B presented with CD27 1 B cell counts (total memory B cells) of greater than 5% of peripheral B lymphocytes, and 6 of them have remained thus far free of noninfectious complications (Table I) . Interestingly, we found a significant association between patients of group A and the presence of noninfectious complications with respect to patients of group B (P < .05, x 2 test). In spite of this strong correlation between SHM, the B-cell immunophenotype, and clinical presentation, patient 25 had reference values for the mutated fraction of VkA27, had autoimmunity, and presented switched memory B cells of less than 2% (Fig 1, B, and Table I ). An important issue is whether the values of hotspot mutations obtained from PBMCs are comparable with those from particular B-cell subsets (ie, memory B cells). For this purpose, we used fluorescence-activated cell sorting to sort CD27 1 B cells and performed IgkREHMA analysis from 7 patients (P8, P11, P12, P17, P18, P20, and P23) presenting with more than 2% of switched memory B cells or more than 10% of total memory B cells and also from 4 healthy donors. The analysis showed that these patients, who initially had reduced levels of mutated fractions of VkA27 on total B cells, continued with reduced level of mutations on memory B cells (Fig  1, D) . Even though the mutation rate could be higher in the switched memory B-cell population with respect to nonswitched memory B cells, even patients with switched memory B-cell counts comparable with those in healthy donors (P20 and P23) had a marked decrease in SHM frequency (Fig 1, D) . Overall, SHM frequencies ranged to less than the reference interval in patients with CVID, even when the analysis was performed specifically in memory B cells.
Studies of CSR
Patients with CVID demonstrate increased microhomology use. To investigate the quality of the DSB repairs in in vivo CSR, we amplified Sm-Sa regions from genomic DNA of patients and control subjects by using a previously described nested PCR. 21 Despite the low levels of serum IgA in our patients, Sm-Sa fragments could be amplified, even if with decreased intensity than in healthy donors (data not shown). Therefore, to assess the nature of switched junctions, we cloned and sequenced 194 Sm-Sa fragments from 20 patients with pediatric CVID (Table II) and 53 fragments from 10 healthy control subjects (Fig 2) . All of the switched fragment sequences were unique and thus represented independent CSR events. Fig 2, A, shows some of the more representative aligned sequences from patients and control subjects.
Globally, we observed a clear decrease in the proportion of blunt junctions (0 bp of homology) in our CVID cohort in comparison with control subjects. Indeed, a significant increase of sequences presenting 7 to 9 bp of microhomology use was observed in patients, even those with more than 10 bp of homology, on the junction repair compared with healthy donors (P < .001 and P < .01, respectively, x 2 test ; Fig 2, B) . Overall, our results showed a significant increase in the extent of donor-acceptor homology on Sm-Sa joints in patients with CVID with respect to healthy control subjects, with a mean perfect sequence homology of 6.9 6 5.3 bp in patients with CVID versus 2.3 6 3.5 bp in healthy control subjects (P <.0001, 2-tailed Student t test; Fig 2, B and C) . The increase in microhomology use was found in 12 (60%) of the 20 evaluated patients (Table II) , and most of the Sm-Sa joints from these patients were flanked by imperfect repeats (see the dashed line boxes in Fig 2, A) . Eleven of the 12 patients displaying abnormal microhomology use had less than 2% of switched memory B cells (Table II) . The remaining 8 patients had no statistical differences with respect to the control group, and 4 of them presented with more than 10% total memory B cells (CD19 1 CD27
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, Table II) . Despite this increased microhomology use, no significant association with clinical noninfectious complications was observed between abnormal and normal microhomology use subgroups of patients (P 5 .26, x 2 test). Altogether, we found a significant correlation between the media of microhomology use in each patient and the proportion of switched memory B cells (Spearman r 5 20.72, P 5 .0003; Fig 2, D) , a significant difference that was not noted when compared with IgG or IgA serum levels before substitution with intravenous gammaglobulin (data not shown). These results indicate CSR deficiency in an important group of patients likely associated with a defective repair of switch junctions.
Analysis of TD and TI stimulation further characterizes patient subgroups. In an attempt to localize the precise step of the CSR defect, we tested the ability to generate GLT (IH-CH), CTs (IH-Cm), and transcripts and to upregulate AICDA in experiments. Data were analyzed by using the 2 2DDCt method with ACTB as a reference gene, considering the relative expression (RE) of AICDA mRNA from the control culture as 1. Statistical analysis was performed by using 1-way ANOVA, followed by the Dunnett multiple comparison posttest. CP < .001; hP < .05. HD, Healthy donors; P, patients. B, Expression of AICDA, Ig-Cg1 (GLTg1), Ig1-Cm (CTg1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; charge control) transcripts by using RT-PCR in PBMCs from patients and control subjects before (2) and after (1) stimulation with CD40L and IL-4. C, Control subject; P, patient. C, qRT-PCR analysis of AICDA in purified naive B cells from 6 patients with CVID and 4 healthy donors cultured for 2 or 4 days with anti-CD40 and IL-4 or CpG and IL-10, respectively. Data were analyzed, as described above. D, Expression of AICDA, Ia-Ca (GLTa), Ia-Cm (CTa), and GAPDH (charge control) transcripts by using RT-PCR in purified naive B cells from 6 patients with CVID and 1 healthy donor before (2) and after (1) stimulation with CD40L and IL-4. C, Control subject; P, patient.
PBMCs before and after being activated in vitro with TD (CD40L and IL-4) and TI (CpG and IL-10) stimuli in 15 patients (P1, P2,  P3, P4, P6, P8, P9, P11, P12, P15, P17, P18, P23, P24, and P25) and 5 healthy donors. Healthy donors' PBMCs showed an increase in the expression of GLTg1 (Ig1-Cg1) and CTg1 (Ig-Cm; Fig 3, B) along with an upregulation of AICDA measured by using RT-PCR and qRT-PCR (Fig 3, A and B) after TD stimuli (similar results were observed by means of TI stimulation, data not shown). By contrast, none of the patients with CVID showed GLTg1, CTg1, and AICDA transcript upregulation by TI stimuli, and they behaved heterogeneously in terms of responsiveness to TD stimuli (Fig 3, A and B) .
Naive B cells obtained from 6 patients with more than 10% of total memory B cells (P8, P11, P12, P17, P18, and P23) and 4 healthy donors were activated in vitro to limit possible effects on transcript induction caused by the presence of memory B cells, as previously described (Fig 3, C and D) . We observed similar results through TI stimulation in naive B cells with respect to that observed in PBMCs. However, through TD stimuli, patients 23 and 18 showed less upregulation of AICDA along with a lack of expression of GLTa and CTa transcripts (Fig 3, D) , as well as GLTg1 and CTg1 expression (data not shown).
Taking these results into account, 3 subgroups were delineated: subgroup 1, lacking response to TD stimulation (P1, P2, P3, P4, P6, P9, P11, P15, and P25); subgroup 2, no expressing GLTs but retaining AICDA activation (P17, P18, and P23); and subgroup 3, showing a similar behavior to the healthy control subjects (P8, P12, and P24).
DISCUSSION
In recent years, analysis of several immunoglobulin deficiencies has made it possible to describe molecular mechanisms underlying the CSR and SHM pathways, which are key elements in the maturation of antibody responses. 28 However, functional defects in the ability to perform CSR might or might not be associated with a defect in SHM. 22, 29, 30 Among the genetic alterations found causing defects on CSR and SHM are those causing hyper-IgM syndromes, such as deficiencies of CD40 and CD40L, 31,32 AICDA, 33 or UNG 34 genes, which helped us understand the essential role of these molecules in B cells for both mechanisms. Thus the study of the ability of B cells to perform SHM and CSR in patients with primary immunodeficiencies could help to identify new proteins involved either in 1 or both pathways. 7, [35] [36] [37] [38] [39] [40] In the present study, by evaluating the qualitative aspects of the antibodies produced by patients with CVID, we described SHM and/or CSR defects in our cohort of pediatric patients. Indeed, even if in our cohort, as reported, 6, 7 low or absent switched memory B cells have mainly been associated with secondary complications, this does not seem consistently related to the ability to trigger CSR. Thus intrinsic CSR events remained unaffected in both patients presenting (P12 and P18) and those lacking (P24) switched memory B cells and noninfectious clinical complications. Likewise, by pointing out specific impairments in antibody production, we can attempt to categorize patients with CVID to guide the search for new genetic targets and correlate treatment based on the clinical course of each category.
The results obtained by analyzing the SHM pathway showed that to a greater or lesser extent, almost all patients with CVID had altered SHM of the antibody light chain, making it possible to group them into 2 categories: (1) severe defect in SHM (group A in the IgkREHMA) and (2) moderate defect in SHM (group B in the IgkREHMA, Table I ). This assay allows analysis of the frequency of mutated Igk transcripts in a CDR mutation hotspot. It is important to note that mutations in this hotspot seem to be positively selected, 41 and the levels of mutated transcripts correlate highly with the percentage of memory B cells. 12 Indeed, in our cohort heterogeneity of SHM correlated with the percentage of switched memory B cells. This correlation could indicate that the light chain mutation levels might relate on the absence of memory subpopulations; however, as previously observed by Andersen et al, 12 we also found a reduced proportion of the mutated fraction on memory B cells sorted from patients with CVID. Furthermore, even patients with a similar fraction of switched memory B cells as healthy donors (P20 and P23) showed a marked decrease in SHM frequency (Fig 1, D) . Thus because a low number of memory B cells cannot fully explain the results of the IgkREHMA in our cohort of patients with CVID, an intrinsic defect in the SHM machinery should not be ruled out, at least in some of them.
By analyzing the clinical aspect of patients in each group of altered SHM, we observed that 6 of 9 patients in group A (severe defect in SHM) presented with autoimmunity, splenomegaly, or granulomas (Table I) . On the other hand, 6 of the 8 patients in group B remained thus far free of noninfectious complications (Table I) . As an important clinical tool, we found a significant association between patients of group A and the presence of noninfectious complications with respect to patients of group B (P < .05, x 2 test). This could potentially make clinicians more aware of noninfectious complications that are more likely to arise in a particular group of patients with CVID and not exhaust valuable resources monitoring patients who are less likely to have noninfectious complications.
To further characterize CVID, B-cell analysis of unique switch junctions representing independent CSR events leads us to distinguish 2 groups of patients: those with a significant increase in the extent of donor-acceptor homology (microhomology) at the Sm-Sa regions and those with switch junctional sequences statistically comparable with healthy donors (Table II) . Despite this increased microhomology use, no significant association with clinical noninfectious complications was observed between abnormal and normal microhomology use subgroups of patients (P 5 .26, x 2 test). The mean microhomology use for each patient correlated with the percentage of switched memory B cells (Fig 2, D) , suggesting that those patients triggering lower but measurable CSR in vivo have less donor-acceptor homology on Sm-Sa joints. By contrast, we could not find any correlation between microhomology use and immunoglobulin serum levels, which seems to be in accordance with the poor predictive value of plasma IgG levels in patients with CVID because even patients with slightly decreased IgG levels can be highly susceptible to infections. 8 In our attempt to stratify patients with CVID according to SHM or CSR analysis, no difference in infection control became evident. As previously reported, the most frequent clinical manifestation in this cohort of patients with CVID was respiratory tract infection, with 43% presenting with upper respiratory tract infections, namely sinusitis and otitis media, and as many as 79% of patients presenting with recurrent lower respiratory tract infections. 23 Almost all of the patients in group A according to SHM assay performance presented with failures in CSR-evaluated mechanisms (P4, P6, P7, P9, P10, P11, P13, P14, P15, and P16).
The presence of microhomology and imperfect repeats are reminiscent of defects in the NHEJ repair pathway. 35, 42, 43 It is important to note that in our CVID cohort no patient presented with clinical or immunologic phenotypes reminiscent of those found in patients with known DNA repair defects. Nevertheless, normal expression of other DNA repair proteins involved in CSR 42, 44, 45 or in repairing AICDA-induced lesions 38, 46 could not be excluded. Similarly, we cannot rule out a defect in a yet uncharacterized molecule involved in NHEJ (S regions in CSR), MMR (Mismatch repair; V regions in SHM), or both or in an alternative pathway of DNA repair involved in both late differentiation processes of B cells. It has been described that patients with mutations in PMS2 with impaired S-region repair have an altered pattern of SHM. 43 However, this defect has been excluded by using PMS2 sequencing in our cohort of patients with CVID. The improved DNA-sequencing technologies (ie, next-generation sequencing) should enable us to elucidate the possible gene defects underlying the observed changes in the near future.
In addition, a defect in proteins activated in response to DNA damage and suppressed in B cells through B-cell lymphoma 6 (Bcl-6) should also be considered. 47 Although, to date, no animal model can support this hypothesis, the identification of genes that are directly repressed by Bcl-6 has strengthened the idea of essential and specialized functions of this protein in germinal center formation. 48, 49 Bcl-6 appears to be crucial for germinal center B cells undergoing the high rates of proliferation required for CSR and SHM. In fact, it has been shown that Bcl-6 suppresses the responses of cell-cycle arrest and apoptosis through suppression of either p53 50 or p21. 47 In this sense it would also be interesting to evaluate the forkhead box protein O1/AKT/phosphoinositide 3-kinase pathway, which is involved in regulation of apoptosis, cell-cycle arrest, differentiation, and longevity of B cells. 51, 52 On the other hand, patients of group B with moderated defect in SHM but correctly repairing S regions (P17, P18, P23, and P24), a defect in an AICDA cofactor exclusively involved in the activation or repair of the V regions, could be considered. The existence of such a cofactor of AICDA has been previously postulated, but no protein playing that role has been identified. 53 However, although P24 was able to activate CSR molecular events in vitro through TD stimuli, P17, P18, and P23 only conserved AICDA activation (Fig 3) . Abnormalities involving a first step of CSR, namely GLT activation, could underlie this condition.
Finally, patients 21 and 25 presented with failure in CSR, with a mildly defective SHM evoking the phenotype caused by mutations in the AICDA C-terminal region. 54, 55 A cofactor acting at the AICDA C-terminal region, which is specifically required for development of CSR and dispensable for SHM, has been also suggested but not yet identified. 53, 56 As an example, defects in the 14-3-3 adapter protein, which is involved in AICDA recruitment to S regions, could be evaluated in these patients, 57 particularly in patient 21, who had an immunologic phenotype reminiscent of defects in genes known to be involved in CSR (ie, hyper-IgM syndromes). However, abnormalities in AICDA, UNG, CD40, CD40L, and PMS2 were ruled out through sequence analysis. Furthermore, normal expression of the inducible costimulator molecule was seen by using flow cytometry, ruling out this deficiency previously described in some patients with CVID. 58, 59 Altogether, molecular definitions of CSR and/or SHM defects in patients with CVID can guide future investigations aiming to further elucidate the complex mechanisms involved in B-cell differentiation pathways. 29, 60 Moreover, clinicians could consider assessments of SHM in patients with CVID in view of the observed correlation between severe impairment and noninfectious complications in pediatric patients with CVID.
